| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ITOS | Common Stock | Sale | -$1.01M | -36.2K | -1.08% | $27.96 | 3.33M | Sep 23, 2021 | See Footnote | F1, F2, F3, F4 |
| transaction | ITOS | Common Stock | Sale | -$20.3K | -717 | -0.02% | $28.38 | 3.33M | Sep 23, 2021 | See Footnote | F1, F5, F6, F7 |
| transaction | ITOS | Common Stock | Sale | -$137K | -4.91K | -0.15% | $27.81 | 3.32M | Sep 24, 2021 | See Footnote | F1, F8, F9, F10 |
| transaction | ITOS | Common Stock | Sale | -$315K | -11.6K | -0.35% | $27.09 | 3.31M | Sep 27, 2021 | See Footnote | F1, F11, F12, F13 |
| Id | Content |
|---|---|
| F1 | Transaction effected pursuant to a plan established pursuant to Rule 10b5-1. |
| F2 | The shares were sold as follows: 21,575 by MPM BioVentures 2014, L.P. ("BV 2014"), 743 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 13,626 by MPM BioVentures 2018, L.P. ("BV 2018") and 269 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC. |
| F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.25 to $28.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F4 | The shares are held as follows: 1,885,806 by BV 2014, 107,713 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 64,908 by AM BV2014, 1,191,035 by BV 2018, 54,213 by MPM BioVentures 2018(B), L.P. ("BV 2018(B)") and 23,505 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. |
| F5 | The shares were sold as follows: 427 by BV 2014, 15 by AM BV2014, 270 by BV 2018 and 5 by AM BV2018. |
| F6 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.26 to $28.46 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The shares are held as follows: 1,885,379 by BV 2014, 107,713 by BV 2014(B), 64,893 by AM BV2014, 1,190,765 by BV 2018, 54,213 by BV 2018(B) and 23,500 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any. |
| F8 | The shares were sold as follows: 2,927 by BV 2014, 101 by AM BV2014, 1,849 by BV 2018 and 36 by AM BV2018. |
| F9 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.39 to $28.26 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F10 | The shares are held as follows: 1,882,452 by BV 2014, 107,713 by BV 2014(B), 64,792 by AM BV2014, 1,188,916 by BV 2018, 54,213 by BV 2018(B) and 23,464 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. |
| F11 | The shares were sold as follows: 6,926 by BV 2014, 238 by AM BV2014, 4,375 by BV 2018 and 86 by AM BV2018. |
| F12 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.95 to $27.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F13 | The shares are held as follows: 1,875,526 by BV 2014, 107,713 by BV 2014(B), 64,554 by AM BV2014, 1,184,541 by BV 2018, 54,213 by BV 2018(B) and 23,378 by AM BV2018. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its respective pecuniary interest therein. |
See Form 4 for MPM BioVentures 2018, L.P for additional members of this joint filing.